HIV Prevention Drug Access Limited by USAID Cuts

New injectable forms of pre‑exposure prophylaxis (PrEP) are poised to transform global HIV prevention, yet a sharp decline in worldwide investment threatens to undermine their impact. The World Health Organization (WHO) last year urged governments to prioritize lenacapavir, a long‑acting injectable that requires only two shots a year, after demonstrating its potential to curb new infections more effectively than daily oral or bimonthly injections.

Experts at the Aids 2026 Conference in Rio de Janeiro warned that cuts to U.S. foreign aid will leave the populations most in need without access to this promising therapy. While PrEP remains 99 % effective when used consistently, the financial shortfall could stall the rollout of lenacapavir in low‑ and middle‑income countries that bear the highest burden of HIV. The conference highlighted that without sustained funding, the gains achieved by existing PrEP modalities may be reversed.

The consensus among researchers is clear: the introduction of long‑acting injectable PrEP could dramatically reduce new HIV cases worldwide, but only if adequate resources are secured. Continued investment is essential to ensure that the benefits of this breakthrough reach those who need them most.